Dave Piacquad

Serving as Independent Member on Biotech Boards
Summary
David Piacquad is a seasoned professional with a rich background in the biotechnology and pharmaceutical industry, having held senior leadership roles at renowned companies like Amgen, Schering-Plough, and Johnson & Johnson.
During his tenure as the Senior Vice President of Strategy and Business Development at Amgen, David was instrumental in driving the company's global expansion through strategic mergers, acquisitions, and alliances, significantly increasing Amgen's global footprint from around 50 to over 100 countries.
His impressive track record includes overseeing major acquisitions such as Five Prime Therapeutics, Otezla, Onyx, and Nuevolution, among others, which have played a crucial role in shaping Amgen's success.
David's expertise extends to spin-outs and start-ups featuring Amgen technology, with notable ventures including Atara, Neumora, Akero, and Kartos, highlighting his commitment to fostering innovation and entrepreneurship in the biotech sector.
Prior to his time at Amgen, David served as the Senior Vice President of Business Development at Schering-Plough, where he led M&A, licensing, and alliance management activities, contributing to significant deals like the merger with Merck and the acquisition of Organon Biosciences.
With over 20 years of experience at Johnson & Johnson, David played a pivotal role in various M&A activities, including mergers with Centocor and ALZA, and acquisitions of Inverness Medical and Aveeno.
David's educational background includes a BA in Philosophy from Colgate University and an MBA in Finance from The Wharton School, reflecting his strong academic foundation to complement his extensive industry knowledge.
Currently based in Vero Beach, Florida, David Piacquad continues to be actively involved in the biotech sector, serving on the board of 3T Bio and Kartos, and contributing his expertise as a lecturer at prestigious business schools.
His specialties in mergers, acquisitions, joint ventures, spin-outs, and equity investments highlight his diverse skill set and leadership in driving strategic growth and innovation within the biotechnology industry.